CIPADI - Centro Integral de Prevencion y Atencion en Diabetes

The trials here

What the 11 trials at this site are about, from their registry records.

Conditions

• Type 2 diabetes6 trials
• Obesity5 trials
• Chronic kidney disease2 trials
• Stroke2 trials
• Type 1 diabetes2 trials
• Coronary artery disease1 trial
• Heart failure1 trial
• High blood pressure1 trial
• Peripheral artery disease1 trial

Phase

• Phase 311 trials

Status

• Active, not recruiting5 trials
• Completed4 trials
• Recruiting2 trials

Lead sponsor

• Eli Lilly and Company9 trials
• Boehringer Ingelheim1 trial
• Pfizer1 trial

Running trials

• Active, not recruiting

  A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)

  NCT07400653· Phase 3· Pfizer· Source

• Recruiting

  A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

  NCT07241390· Phase 3· Eli Lilly and Company· Source

  Contact: Pedro Rosario Fabian Calella (principal investigator)

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Active, not recruiting

  A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight

  NCT06962280· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

  NCT06383390· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

  NCT06260722· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

  NCT05556512· Phase 3· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic kidney disease1 recruiting
• High blood pressure1 recruiting
• Stroke1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

  NCT05882045· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)

  NCT05662332· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

  NCT05463744· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin

  NCT05275400· Phase 3· Eli Lilly and Company· Source